†Medicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States.
‡Division of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, United States.
J Med Chem. 2015 Jul 23;58(14):5609-19. doi: 10.1021/acs.jmedchem.5b00682. Epub 2015 Jul 8.
Three photoaffinity ligands (PALs) for the human serotonin transporter (hSERT) were synthesized based on the selective serotonin reuptake inhibitor (SSRI), (S)-citalopram (1). The classic 4-azido-3-iodo-phenyl group was appended to either the C-1 or C-5 position of the parent molecule, with variable-length linkers, to generate ligands 15, 22, and 26. These ligands retained high to moderate affinity binding (K(i) = 24-227 nM) for hSERT, as assessed by [(3)H]5-HT transport inhibition. When tested against Ser438Thr hSERT, all three PALs showed dramatic rightward shifts in inhibitory potency, with Ki values ranging from 3.8 to 9.9 μM, consistent with the role of Ser438 as a key residue for high-affinity binding of many SSRIs, including (S)-citalopram. Photoactivation studies demonstrated irreversible adduction to hSERT by all ligands, but the reduced (S)-citalopram inhibition of labeling by [(125)I]15 compared to that by [(125)I]22 and [(125)I]26 suggests differences in binding mode(s). These radioligands will be useful for characterizing the drug-protein binding interactions for (S)-citalopram at hSERT.
基于选择性 5-羟色胺再摄取抑制剂(SSRI)西酞普兰(1),合成了三种用于人血清素转运蛋白(hSERT)的光亲和配体(PAL)。经典的 4-叠氮-3-碘苯基团被附加到母体分子的 C-1 或 C-5 位置,带有可变长度的接头,生成配体 15、22 和 26。这些配体通过 [(3)H]5-HT 转运抑制评估,保留了对 hSERT 的高到中等亲和力结合(K(i) = 24-227 nM)。当针对 Ser438Thr hSERT 进行测试时,所有三种 PAL 都表现出抑制效力的明显右移,Ki 值范围为 3.8 至 9.9 μM,与 Ser438 作为许多 SSRIs(包括西酞普兰)高亲和力结合的关键残基的作用一致。光激活研究表明所有配体均不可逆地加合物到 hSERT,但与 [(125)I]22 和 [(125)I]26 相比,[(125)I]15 对标记的(S)-西酞普兰抑制减少表明结合模式存在差异。这些放射性配体将有助于表征 hSERT 中西酞普兰的药物-蛋白结合相互作用。